Literature DB >> 9659147

The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

I G McFarlane1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9659147      PMCID： PMC1727103          DOI： 10.1136/gut.42.5.599

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  46 in total

1.  Sera with high levels of anti-smooth muscle and anti-mitochondrial antibodies frequently bind to cytoskeleton proteins.

Authors:  G Dighiero; P Lymberi; C Monot; N Abuaf
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

2.  Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis.

Authors:  J C Homberg; N Abuaf; O Bernard; S Islam; F Alvarez; S H Khalil; R Poupon; F Darnis; V G Lévy; P Grippon
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

3.  Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2.

Authors:  E Martini; N Abuaf; F Cavalli; V Durand; C Johanet; J C Homberg
Journal:  Hepatology       Date:  1988 Nov-Dec       Impact factor: 17.425

4.  Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors.

Authors:  P T Donaldson; D G Doherty; K M Hayllar; I G McFarlane; P J Johnson; R Williams
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

5.  Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity.

Authors:  M Lenzi; P J Johnson; I G McFarlane; G Ballardini; H M Smith; B M McFarlane; C Bridger; D Vergani; F B Bianchi; R Williams
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis.

Authors:  A J Czaja; J E Hay; J Rakela
Journal:  Mayo Clin Proc       Date:  1990-01       Impact factor: 7.616

8.  Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen.

Authors:  M Manns; G Gerken; A Kyriatsoulis; M Staritz; K H Meyer zum Büschenfelde
Journal:  Lancet       Date:  1987-02-07       Impact factor: 79.321

9.  HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies.

Authors:  I R Mackay; B D Tait
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

10.  Type 2 autoimmune hepatitis and hepatitis C virus infection.

Authors:  M Lenzi; G Ballardini; M Fusconi; F Cassani; L Selleri; U Volta; D Zauli; F B Bianchi
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321
View more
  11 in total

Review 1.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

2.  Relationship between autoimmune hepatitis and HLA-DR4 and DRbeta allelic sequences in the third hypervariable region in Chinese.

Authors:  X Ma; D K Qiu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Type 1 autoimmune hepatitis in Taiwan: diagnosis using the revised criteria of the International Autoimmune Hepatitis Group.

Authors:  Lok-Beng Koay; Ching-Yih Lin; Sun-Lung Tsai; Chuan Lee; Ching-Nan Lin; Ming-Juen Sheu; Hsing-Tao Kuo; Chi-Shu Sun
Journal:  Dig Dis Sci       Date:  2006-10-20       Impact factor: 3.199

4.  Diffuse systemic sclerosis and autoimmune hepatitis: a unique association.

Authors:  Carlos Ewerton Maia Rodrigues; Cláudia Lobato Borges; Jozélio Freire de Carvalho
Journal:  Clin Rheumatol       Date:  2010-02-07       Impact factor: 2.980

Review 5.  Autoimmune hepatitis--approach to diagnosis.

Authors:  Albert J Czaja
Journal:  MedGenMed       Date:  2006-05-23

6.  Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.

Authors:  M Baeres; J Herkel; A J Czaja; I Wies; S Kanzler; E L R Cancado; G Porta; M Nishioka; T Simon; C Daehnrich; W Schlumberger; P R Galle; A W Lohse
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

7.  Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis.

Authors:  Dolores B Njoku; Jenelle L Mellerson; Monica V Talor; Douglas R Kerr; Nauder R Faraday; Ingrid Outschoorn; Noel R Rose
Journal:  Clin Vaccine Immunol       Date:  2006-02

8.  Histological remission of autoimmune hepatitis after the addition of allopurinol and azathioprine dose reduction.

Authors:  Ana Luiza Vilar Guedes; Adriana Ribas Andrade; Vinicius Santos Nunes; Fabiana Roberto Lima; Evandro Sobroza de Mello; Suzane Kioko Ono; Débora Raquel Benedita Terrabuio; Eduardo Luiz Rachid Cançado
Journal:  Autops Case Rep       Date:  2017-06-30

9.  Development of systemic sclerosis in patients with autoimmune hepatitis: an emerging overlap syndrome.

Authors:  Roberto Assandri; Marta Monari; Alessandro Montanelli
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016

10.  Role of age in presentation, response to therapy and outcome of autoimmune hepatitis.

Authors:  Martine A M C Baven-Pronk; Maaike Biewenga; Joanne J van Silfhout; Aad P van den Berg; Henk R van Buuren; Bart J Verwer; Carin M J van Nieuwkerk; Gerd Bouma; Bart van Hoek
Journal:  Clin Transl Gastroenterol       Date:  2018-07-02       Impact factor: 4.488
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.